文献速递临床试验与 GCP基础与转化研究

母亲补充DHA对母乳喂养早产儿无支气管肺发育不良生存的影响:随机临床试验

Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

这项在16个加拿大NICU开展的超优效性安慰剂对照随机试验,纳入232名DHA组母亲(273名婴儿)和229名安慰剂组母亲(255名婴儿),因中期数据提示潜在危害而提前终止。

要点

  • 母亲补充DHA未显著改善早产儿无BPD生存率,绝对差异-5.0%(95%CI -11.6%至2.6%)。
  • 试验因潜在危害担忧提前终止,结果解释受限。

核心结论

  • 对于胎龄小于29周的母乳喂养早产儿,新生儿期母亲补充DHA相比安慰剂未显著改善校正胎龄36周时的无支气管肺发育不良生存率。
  • 研究解释受提前终止限制。

研究设计与样本

  • 超优效性、安慰剂对照随机临床试验,在16个加拿大新生儿重症监护病房开展,时间为2015年6月至2018年4月,末次婴儿随访至2018年7月。
  • 纳入分娩胎龄小于29周的哺乳期妇女,于分娩后72小时内入组;计划入组800名母亲,但提前终止。
  • 232名母亲(273名婴儿)随机分配至口服胶囊提供1.2 g/d DHA组,从随机化至校正胎龄36周;229名母亲(255名婴儿)分配至安慰剂组。
  • 共461名母亲及其528名婴儿(平均胎龄26.6周,SD 1.6周;253名[47.9%]女性),375名母亲(81.3%)和523名婴儿(99.1%)完成试验。

主要发现

  • 22个预设次要结局中,19个无显著差异。

临床怎么用

  • 对于胎龄小于29周的母乳喂养早产儿,母亲新生儿期补充DHA(1.2 g/d至校正胎龄36周)未显示改善无BPD生存的获益。
  • DHA组存活婴儿BPD发生率更高,临床决策需权衡潜在风险。

局限性

  • 试验因基于本试验及同期另一试验的中期数据担忧危害而提前终止,统计效能不足,结果解释受限。
  • 计划入组800名母亲,实际入组461名母亲及528名婴儿,样本量未达目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Maternal docosahexaenoic acid (DHA) supplementation may prevent bronchopulmonary dysplasia, but evidence remains inconclusive. OBJECTIVE: To determine whether maternal DHA supplementation during the neonatal period improves bronchopulmonary dysplasia-free survival in breastfed infants born before 29 weeks of gestation. DESIGN, SETTING, AND PARTICIPANTS: Superiority, placebo-controlled randomized clinical trial at 16 Canadian neonatal intensive care units (June 2015-April 2018 with last infant follow-up in July 2018). Lactating women who delivered before 29 weeks of gestation were enrolled within 72 hours of delivery. The trial intended to enroll 800 mothers, but was stopped earlier. INTERVENTIONS: There were 232 mothers (273 infants) assigned to oral capsules providing 1.2 g/d of DHA from randomization to 36 weeks' postmenstrual age and 229 mothers (255 infants) assigned to placebo capsules. MAIN OUTCOMES AND MEASURES: The primary outcome was bronchopulmonary dysplasia-free survival in infants at 36 weeks' postmenstrual age. There were 22 secondary outcomes, including mortality and bronchopulmonary dysplasia. RESULTS: Enrollment was stopped early due to concern for harm based on interim data from this trial and from another trial that was published during the course of this study. Among 461 mothers and their 528 infants (mean gestational age, 26.6 weeks [SD, 1.6 weeks]; 253 [47.9%] females), 375 mothers (81.3%) and 523 infants (99.1%) completed the trial. Overall, 147 of 268 infants (54.9%) in the DHA group vs 157 of 255 infants (61.6%) in the placebo group survived without bronchopulmonary dysplasia (absolute difference, -5.0% [95% CI, -11.6% to 2.6%]; relative risk, 0.91 [95% CI, 0.80 to 1.04], P = .18). Mortality occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13], P = .12). Bronchopulmonary dysplasia occurred in 41.7% of surviving infants in the DHA group vs 31.4% in the placebo group (absolute difference, 11.5% [95% CI, 2.3% to 23.2%]; relative risk, 1.36 [95% CI, 1.07 to 1.73], P = .01). Of 22 prespecified secondary outcomes, 19 were not significantly different. CONCLUSIONS AND RELEVANCE: Among breastfed preterm infants born before 29 weeks of gestation, maternal docosahexaenoic acid supplementation during the neonatal period did not significantly improve bronchopulmonary dysplasia-free survival at 36 weeks' postmenstrual age compared with placebo. Study interpretation is limited by early trial termination. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02371460.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Marc I, Piedboeuf B, Lacaze-Masmonteil T, et al. Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial. JAMA. 2020. PMID: 32662862. doi:10.1001/jama.2020.8896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。